Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

Core Viewpoint - Oculis Holding AG reported significant clinical advancements and financial results for the year 2024, highlighting its commitment to developing innovative treatments for ophthalmic and neuro-ophthalmic diseases, with a strong focus on executing its late-stage clinical portfolio in 2025 [2][6][18] Clinical Highlights and Upcoming Milestones - The company achieved positive Phase 2 topline results from the ACUITY trial for Privosegtor (OCS-05) in acute optic neuritis and the RELIEF trial for Licaminlimab (OCS-02) in dry eye disease [2][6] - Enrollment for the Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema (DME) is on track to be completed in the coming months, with top-line data expected in the first half of 2026 [7] - A $100 million equity financing was successfully completed to support the advancement of the clinical portfolio [6][8] Financial Highlights - As of December 31, 2024, the company had total cash, cash equivalents, and short-term investments of CHF 98.7 million or$109.0 million, an increase from CHF 91.7 million or $108.9 million at the end of 2023 [5][8] - The net loss for Q4 2024 was CHF 28.7 million or$32.6 million, compared to CHF 12.5 million or $14.1 million for the same period in 2023 [10][14] - For the full year 2024, the net loss was CHF 85.8 million or$97.4 million, a slight decrease from CHF 88.8 million or $98.8 million in 2023 [10][14] Research and Development Expenses - Research and development expenses for Q4 2024 were CHF 11.8 million or$13.4 million, up from CHF 8.0 million or $9.0 million in Q4 2023 [10][14] - For the full year 2024, research and development expenses totaled CHF 52.1 million or$59.1 million, compared to CHF 29.2 million or $32.6 million in 2023 [10][14] Future Outlook - The company plans to provide further updates on its business and pipeline development during the R&D Day scheduled for April 15, 2025, in New York City [4][6]